A multidisciplinary approach to squamous cell carcinomas of the head and neck: What is new?

Current Opinion in Oncology

Volumn 18, Issue 3, 2006, Pages 253-257

  Licitra, Lisa ^a,b   Bossi, Paolo ^a   Locati, Laura D ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Cancer Medicine Department   (Italy)

Author keywords

Head and neck cancer; Multidisciplinary; Review

Indexed keywords

ALOE VERA EXTRACT; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ERYTHROPOIETIN; FLUOROURACIL; GEFITINIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TUMOR VACCINE;

ACNE; ANEMIA; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG INFUSION; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUROTOXICITY; NUTRITIONAL SUPPORT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION INJURY; RASH; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

CARCINOMA, SQUAMOUS CELL; DISEASE MANAGEMENT; HEAD AND NECK NEOPLASMS; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM;

EID: 33646698385     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000219254.53091.35     Document Type: Review

References (52)

1. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005.
2. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005; 55:242-258. This is an excellent review of the latest TNM classification.
3. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46:135-146.
4. Overgaard J, Eriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005; 6:757-764.
5. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46:253-260.
6. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23:5560-5567. This describes interesting work about the predictive role of EGFR in an accelerated regimen of radiotherapy.
7. Eriksen JG, Steiniche T, Overgaard J, et al. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 2005; 74:93-100.
8. Hamana K, Uzawa K, Ogawara K, et al. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer 2005; 92:2181-2184.
9. Ikebe T, Seki K, Nakamura S, et al. Severity of oral mucositis correlates with the response of oral cancer to preoperative radiochemotherapy. Int J Oral Maxillofac Surg 2005; 34:642-645. This paper analyses a possible correlation between intensity of treatment side-effect mucositis and response to therapy.
10. Argiris A. Induction chemotherapy for head and neck cancer: will history repeat itself? J Natl Compr Canc Netw 2005; 3:393-403.
11. Garden AS. Is there still a role for induction chemotherapy for head and neck cancer? J Clin Oncol 2005; 23:1059-1060.
12. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355:949-955.
13. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96:1714-1717. This interesting work reports a benefit for induction chemotherapy in the subgroup of inoperable patients.
14. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23:8636-8645. Adding paclitaxel showed a trend for better outcome with lower toxicity especially for unrespectable tumours in respect to standard chemotherapy (platinum-fluorouracil), with lower toxicity in subsequent radio-chemotherapy.
15. Vermorken JB, Remenar E, Van Herpen C, et al. Standard cisplatin/infusional 5 fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC, #24971) [abstract]. J Clin Oncol 2004; 22:490s.
16. Haddad RI, Tishler R, Wirth L, et al. Rate of complete pathologic response (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2005; 23:502s.
17. Smaradottir A, Siddiqi A, Ray C, et al. Increased incidence of cardiotoxicity after infusional 5-fluorouracil, cisplatin and docetaxel combination chemotherapy in patients with locally advanced head and neck cancer. J Clin Oncol 2005; 23:516s.
18. Vokes E. Current treatments and promising investigations in a multidisciplinary setting. Ann Oncol 2005; 16 (Suppl 6):vi25-vi30.
19. Lefebvre JL Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005; 16 (Suppl 6):vi7-vi12.
20. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer 2005; 93:279-286. This randomized study compared surgery plus radiotherapy and chemo-radiotherapy.
21. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. This is an update of a randomized study of radiotherapy plus cetuximab, which confirmed a benefit in outcome for the addition of cetuximab to radiation.
22. Su YB, Kraus DH, Zelefsky MJ, et al. Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): updated results of a novel combined modality paradigm [abstract]. J Clin Oncol 2005; 23:507s.
23. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
24. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
25. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27:843-850. This provides a comparative analysis of the previous studies [23,24] and identifies strong pathologic risk factors.
26. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 2005; 23:5805-5813.
27. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97:481-488. A detrimental effect was shown for the use of antioxidant vitamins as chemoprevention.
28. Su CK, Mehta V, Ravikumar L, et al. Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. Int J Radiat Oncol Biol Phys 2004; 60:171-177.
29. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260.
30. Lai SY, Childs EE, Xi S, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005; 24:4442-4449. Possible molecular explanations are given of the lower survival obtained with the adjunct of erythropoietin to radiotherapy in a previous study [29].
31. Rabinovitch R, Grant B, Berkey BA, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: A secondary analysis of RTOG trial 90-03. Head Neck 2005; [Epub ahead of print].
32. Ravasco P, Monteiro-Grillo I, Marques Vidai P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005; 27:659-668.
33. Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31:734-743.
34. Choong NW, Cohen EE. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol 2005; [Epub ahead of print].
35. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-8654.
36. Vermorken JB, Bourhis J, Trigo J, et al. Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. J Clin Oncol 2005; 23:501s. This is a comparison of three studies with cetuximab in recurrent/metastatic head and neck cancer.
37. Baselga J, Trigo JM, Bourhis J, et al. Phase Il multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
38. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
39. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase Il study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23:3568-3576.
40. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
41. Cohen EE, Kane MA, List MA, et al. Phase Il trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cli Cancer Res 2005; 11:8418-8424.
42. Cohen EE, Haraf DJ, Stenson M, et al. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC): a phase II trial [abstract]. J Clin Oncol 2005; 23:501s.
43. Su YB, Kraus DH, Zelefsky MJ, et al. Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): Updated results of a novel combined modality paradigm [abstract]. J Clin Oncol 2005; 23:507s.
44. Kim ES, Kies M, Sabichi A, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) [abstract]. J Clin Oncol 2005; 23:511s.
45. Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol 2005; 23:515s.
46. Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC) [abstract]. J Clin Oncol 2005; 23:501s.
47. Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:6976-6981. This was a phase I study of epidermal growth factor receptor and cyclooxigenase-2 inhibitors.
48. Thiery-Vuillemin A, Nguyen T, Pivot X, et al. Molecularly targeted agents: their promise as cancer chemopreventive interventions. Eur J Cancer 2005; 41:2003-2015. This is a review of targeted therapies in the chemopreventive setting.
49. Timar J, Ladanyi A, Forster-Horvath C, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol 2005; 23:3421-3432.
50. Karcher J, Dyckhoff G, Beckhove P, et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 2004; 64:8057-8061.
51. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:3562-3567. No survival difference was shown between a cisplatin plus fluorouracil versus a cisplatin plus paclitaxel scheme in recurrent/metastatic setting.
52. Argiris A, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101:2222-2229.